Complement 3 Glomerulopathy Market - Top Companies and Manufacturers

Companies Dominating the Complement 3 Glomerulopathy Landscape

Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Apellies Pharmaceutical
Amyndas Pharmaceuticals SA
Kira Pharmaceuticals
Alexion Pharmaceuticals Inc.
Omeros Corporation
Amgen Inc.
Sobi®
Boehringer Ingelheim International GmbH.
AstraZeneca

Browse Key Market Insights with Data Illustration:

Complement 3 Glomerulopathy Market Size & Share, Forecast Report 2036

In the News

Positive topline findings from the six-month, double-blind Phase III APPEAR-C3G study of iptacopan for the treatment of patients with C3 glomerulopathy (C3G)1 were released by Novartis today. The primary goal of the research was achieved, as iptacopan (200 mg twice daily) showed superiority over placebo in reducing proteinuria (protein in urine) on top of background medication in a way that was both clinically relevant and statistically significant at six months1. Iptacopan's safety profile matched data1-3 that had previously been published.
Positive findings from the Phase 2 NOBLE study examining pegcetacoplan for the treatment of post-transplant recurrence of primary immune complex membranproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) will be presented at the Kidney Week Annual Meeting of the American Society of Nephrology (ASN), from Sobi® and Apellis Pharmaceuticals, Inc.

Frequently Asked Questions (FAQ)

Increased Incidences of Kidney Disorders, Growing Research and Development Activities in Kidney Diseases, and Increased Awareness Regarding the Disease are the major factors driving the growth of the Complement 3 Glomerulopathy (C3G) market.

The market size of Complement 3 Glomerulopathy (C3G) is anticipated to attain a CAGR of 3% over the forecast period, i.e., 2024-2036.

The major players in the market are Novartis AG, Apellies Pharmaceutical, Amyndas Pharmaceuticals SA, Kira Pharmaceuticals, Alexion Pharmaceuticals Inc., Omeros Corporation, Amgen Inc., Sobi, Boehringer Ingelheim International GmbH., AstraZeneca, and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Complement 3 Glomerulopathy Market - Top Companies and Manufacturers

Companies Dominating the Complement 3 Glomerulopathy Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the Complement 3 Glomerulopathy (C3G) market?

What would be the CAGR of the Complement 3 Glomerulopathy (C3G) market over the forecast period?

Who are the major players dominating the Complement 3 Glomerulopathy (C3G) market?

Which segment captures the largest market size in the end-user segment in the Complement 3 Glomerulopathy (C3G) market?

Which region will provide more business opportunities for the growth of the Complement 3 Glomerulopathy (C3G) market in the future?